DCT

MedRhythms Selects Curavit as its Contract Research Organization (CRO) for a Chronic Stroke Decentralized Clinical Trial

Retrieved on: 
Wednesday, September 20, 2023

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announced that it was selected as the VCRO for a study of MR-001, MedRhythms' neurorehabilitation system designed to improve walking and ambulation in adults with chronic stroke walking impairments. The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial. This will also include evaluating patient engagement and therapeutic response durability.  

Key Points: 
  • The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial.
  • Curavit is responsible for managing all aspects of MedRhythms' hybrid decentralized clinical trial (DCT) – from protocol finalization and Institutional Review Board (IRB) approvals to patient recruitment, testing at physical sites, remote site and patient monitoring and healthcare economics and outcomes analysis.
  • Health economics research quantifies the long-term financial impact for patients, providers, and payers," said Owen McCarthy, President and co-founder of MedRhythms.
  • MR-001 is based on Rhythmic Auditory Stimulation (RAS), a clinical intervention utilizing the mechanism of auditory-motor entrainment ("entrainment").

Global Automotive Flywheel Market Eyes $9.5 Billion Value by 2030: Steady Growth with 3.7% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023

The global Automotive Flywheel Market is poised for remarkable growth, projected to achieve a significant value of $9.5 billion by 2030.

Key Points: 
  • The global Automotive Flywheel Market is poised for remarkable growth, projected to achieve a significant value of $9.5 billion by 2030.
  • The market is expected to experience a steady Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period.
  • The automotive industry has witnessed consistent improvements in kinetic energy recovery systems, leading to enhanced flywheel designs and materials.
  • Prominent market players are expected to seize numerous growth opportunities due to technological advancements in kinetic energy recovery technologies throughout the forecast period.

Point Source Youth Scales Direct Cash Transfers as Prevention for Youth Homelessness to Five U.S. Cities

Retrieved on: 
Tuesday, September 12, 2023

Point Source Youth (PSY), with partners across the U.S., have generated a growing body of evidence and practice knowledge on effectively implementing Direct Cash Transfer interventions with young people.

Key Points: 
  • Point Source Youth (PSY), with partners across the U.S., have generated a growing body of evidence and practice knowledge on effectively implementing Direct Cash Transfer interventions with young people.
  • Building on the incredibly successful Homeless Prevention and Diversion Fund (HPDF) model developed by A Way Home Washington , PSY is scaling the model of using Direct Cash Transfers as a homelessness prevention intervention for young people.
  • "Henry Street Settlement is proud to be a partner in the national launch of Point Source Youth's visionary Direct Cash Transfers as Prevention program to prevent youth homelessness," said David Garza, Henry Street president and CEO.
  • Through the DCT-P pilot, YOTO hopes to learn more about how direct cash transfers can help alumni youth obtain a faster path out of housing instability.

OpenClinica Bolsters Decentralized Clinical Trials Toolkit

Retrieved on: 
Thursday, September 7, 2023

NEEDHAM, Mass., September 7th, 2023 /PRNewswire-PRWeb/ -- OpenClinica debuts eConsent, a complete digital consent solution for improved efficiency, access and patient engagement in clinical trials. OpenClinica Consent is an important addition to the company's decentralized clinical trials (DCT) toolkit, which also includes:

Key Points: 
  • OpenClinica's DCT toolkit improves patient engagement, access and diversity
    NEEDHAM, Mass., September 7th, 2023 /PRNewswire-PRWeb/ -- OpenClinica debuts eConsent , a complete digital consent solution for improved efficiency, access and patient engagement in clinical trials.
  • OpenClinica Consent is an important addition to the company's decentralized clinical trials (DCT) toolkit, which also includes:
    OpenClinica UniteTM, an award-winning EHR to EDC integration technology that automates source data acquisition from EHRs and EMRs to clinical trial research databases (EDCs) and case report forms (eCRFs) at scale.
  • "At OpenClinica, we have long been committed to helping sites and sponsors improve patient participation, engagement and diversity in clinical trials," said Ben Baumann, OpenClinica Co-Founder and Chief Operating Officer.
  • In May 2023, the U.S. Food and Drug Administration released new draft guidance to advance decentralized clinical trials.

The Art of Decentralizing Pediatric Rare Disease Studies: Clinical Trials Suited for Daily Life, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 6, 2023

TORONTO, Sept. 6, 2023 /PRNewswire-PRWeb/ -- Pediatric rare disease trials combine rarity of disease with a restricted and geographically-dispersed population of vulnerable subjects for research, creating unique challenges for study design and execution. Recruitment is challenging, as patients, parents and caregivers need to juggle school schedules, work responsibilities and family obligations to accommodate study participation.

Key Points: 
  • In this webinar, attendees will learn about the challenges of conducting clinical research in pediatric rare diseases.
  • Hear about the potential applications, risks, key considerations and future trends of DCT approaches in pediatric rare disease studies.
  • TORONTO, Sept. 6, 2023 /PRNewswire-PRWeb/ -- Pediatric rare disease trials combine rarity of disease with a restricted and geographically-dispersed population of vulnerable subjects for research, creating unique challenges for study design and execution.
  • Join this webinar to learn the challenges of conducting clinical research in pediatric rare diseases.

Alfa Romeo Announces Return of the Legendary 33 Stradale: Daring to Dream

Retrieved on: 
Wednesday, August 30, 2023

Produced by the Alfa Romeo Centro Stile, the new 33 Stradale is inspired by the historic 1967 model, with enrichments to the sculptural beauty and design elements from Alfa Romeo's new language of style.

Key Points: 
  • Produced by the Alfa Romeo Centro Stile, the new 33 Stradale is inspired by the historic 1967 model, with enrichments to the sculptural beauty and design elements from Alfa Romeo's new language of style.
  • The exterior features a perfect balance of proportions, volumes and surface properties to achieve the epitome of Alfa Romeo's necessary beauty.
  • The award-winning Alfa Romeo Giulia delivers race-inspired performance, advanced technologies and an exhilarating driving experience to the premium midsize sedan segment.
  • Alfa Romeo is part of the portfolio of brands offered by leading global automaker and mobility provider Stellantis.

Clinical Trial Diversity: Harnessing the Power of Technology for More Inclusive Studies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, August 28, 2023

TORONTO, Aug. 28, 2023 /PRNewswire-PRWeb/ -- In today's rapidly evolving healthcare landscape, the need for clinical trial diversity and inclusivity has become a regulatory imperative. However, traditional recruitment methods often fall short in reaching underrepresented populations, leading to a lack of diversity in clinical research studies. This webinar aims to explore how technology can be harnessed to overcome barriers to clinical trial participation and create more inclusive clinical trials.

Key Points: 
  • The featured speakers will discuss how applying new innovative trial designs, like virtual and mobile sites, can broaden patient access.
  • The speakers also will share how decentralized solutions, such as wearables/sensors, home healthcare services, pharmacy networks and micro-sampling technology are improving accessibility.
  • This webinar aims to explore how technology can be harnessed to overcome barriers to clinical trial participation and create more inclusive clinical trials.
  • This webinar highlights the transformative power of technology in clinical trials, enabling accurate study requirements, diverse applications and optimized protocols for patient populations.

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 14, 2023

SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended June 30, 2023, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended June 30, 2023, and provides an update on recent company developments.
  • “Positive momentum established last quarter has accelerated into the second quarter of 2023,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  • In the second quarter of 2022, the Company paid $300 for the one-time exclusive right to negotiate for the acquisition of Dynamic Cell Therapeutics (DCT).
  • Net loss for the second quarter of 2023 was $9,830 compared to a net loss $6,672 for the second quarter of 2022.

Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients

Retrieved on: 
Tuesday, May 30, 2023

Avance Clinical's Chief Scientific Officer, Gabriel Kremmidiotis

Key Points: 
  • Avance Clinical's Chief Scientific Officer, Gabriel Kremmidiotis
    According to Avance Clinical's Chief Scientific Officer Gabriel Kremmidiotis who is part of the Avance Clinical team attending ASCO:
    "Recently, Phase I clinical trial designs in Oncology patients have become more elaborate and include elements of dose escalation, dose expansion and assessment of drug combinations.
  • This, in addition to the increasing number of new emerging therapeutics, has increased the demand for fast progress through the early phases of development and a greater demand for access to patients."
  • "Utilizing Australia's regulatory environment and high-quality oncology experts, Avance Clinical is able to facilitate a fast project launch and seamless transition across different parts of modular oncology protocol designs.
  • Avance Clinical is at the cutting edge of clinical trial technology and has recently been ranked as the world leader in decentralised clinical trials (DCT) technology adoption by GlobalData and Clinical Trial Arena in the CRO sector.

Avance Clinical Joins Global Heath Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies

Retrieved on: 
Thursday, May 25, 2023

The campaign is a collection of interviews and video documentaries, highlighting international business leaders and healthcare specialists from various industries.

Key Points: 
  • The campaign is a collection of interviews and video documentaries, highlighting international business leaders and healthcare specialists from various industries.
  • Avance Clinical CEO, Yvonne Lungershausen and Executive VP North American Operations John Mann will be attending the Global Health Summit and Yvonne will be a leading panelist.
  • Avance Clinical is at the cutting edge of clinical trial technology and has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector.
  • The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking.